AGA Medical Corporation has received European CE Mark approval for its AMPLATZER Vascular Plug 4, AVP 4. The device, which is indicated for arterial and venous embolizations in the peripheral vasculature, uses AMPLATZER’s proven mesh-braided Nitinol technology and may eliminate the need for catheter exchange, giving physicians a more efficient procedure. AGA Medical will begin marketing the AVP 4 in Europe immediately.
“The AVP 4 is a major technological advancement in the AMPLATZER Vascular Plug Family and receiving CE Mark approval validates this achievement,” said John Barr, president and chief executive officer, AGA Medical Corporation.
With its low profile, the AVP 4 allows delivery through a standard 0.038 diagnostic catheter. The physician can choose to use one AVP 4 instead of what often becomes multiple coil implants without factoring in the need for a catheter exchange.
“Our physician customers requested a lower-profile option and we delivered, exceeding their expectations with the AVP 4,” Barr explained. “The AVP 4 complements our other vascular plugs, providing physicians with advanced tools to treat vascular conditions, which have the potential to reduce procedure times while offering improved flexibility and cost effectiveness.”
The AVP 4 is a single-device solution for peripheral embolization, the practice of reducing or eliminating blood flow to an area of the body by blocking or occluding a blood vessel to treat a wide range of circulatory and internal organ diseases. The lower-profile AVP 4 extends the reach of the AMPLATZER Vascular Plug Family to smaller and often more distal vasculature. The device’s multi-layered, double-lobed design provides rapid embolization. Additionally, the flexible mesh and floppy distal section of the delivery wire facilitates easy tracking through torturous anatomy.